Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial

Mov Disord. 2022 May;37(5):1079-1087. doi: 10.1002/mds.28953. Epub 2022 Feb 13.

Abstract

Background: Patients with Parkinson's disease might develop treatment-resistant axial dysfunction after bilateral subthalamic stimulation.

Objectives: To study whether lateralized stimulation (unilateral 50% amplitude reduction) for ≥21 days results in ≥0.13 m/s faster gait velocity in the dopaminergic ON state in these patients, and its effects on motor and axial function, quantitative gait and speech measures, quality of life, and selected cognitive tasks.

Methods: Randomized, double-blinded, double-crossover trial.

Results: In 22 participants (51-79 years old, 15 women), there were no significant changes in gait velocity, quality of life, cognitive, and speech measures. Reducing left-sided amplitude resulted in a 2.5-point improvement in axial motor Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (P = 0.005, uncorrected) and a 1.9-point improvement in the Freezing of Gait Questionnaire (P = 0.024, uncorrected).

Conclusions: Lateralized subthalamic stimulation does not result in meaningful improvement in gait velocity in patients with Parkinson's disease who develop treatment-resistant axial dysfunction after bilateral subthalamic stimulation. Left subthalamic overstimulation may contribute to axial deterioration in these patients. © 2022 International Parkinson and Movement Disorder Society.

Trial registration: ClinicalTrials.gov NCT03462082.

Keywords: Parkinson's disease; asymmetry; axial motor function; deep brain stimulation; lateralization.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Deep Brain Stimulation* / methods
  • Female
  • Gait Disorders, Neurologic* / etiology
  • Gait Disorders, Neurologic* / therapy
  • Humans
  • Middle Aged
  • Parkinson Disease* / complications
  • Parkinson Disease* / therapy
  • Quality of Life
  • Subthalamic Nucleus* / physiology
  • Treatment Outcome

Associated data

  • ClinicalTrials.gov/NCT03462082